Celecoxib - Pfizer/Astellas Pharma

Drug Profile

Celecoxib - Pfizer/Astellas Pharma

Alternative Names: Celebra; Celebrex; Celecox; Niflam; Onsenal; SC-58635; YM-177

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pfizer
  • Developer Astellas Pharma; Dana-Farber Cancer Institute; Department of Veterans Affairs; Linkoping University Hospital; Pfizer; Swedish Lung Cancer Study Group; University of Connecticut; Zydus Cadila
  • Class Antirheumatics; Non-opioid analgesics; Nonsteroidal anti-inflammatories; Pyrazoles; Small molecules; Sulfonamides
  • Mechanism of Action Cyclo-oxygenase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Familial adenomatous polyposis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acute pain; Ankylosing spondylitis; Back pain; Cervicobrachial syndrome; Dental pain; Dysmenorrhoea; Familial adenomatous polyposis; Juvenile rheumatoid arthritis; Osteoarthritis; Pain; Periarthritis; Postoperative pain; Rheumatic disorders; Rheumatoid arthritis; Tendinitis; Tenosynovitis
  • Phase III Non-small cell lung cancer
  • Phase II Stomatitis
  • Discontinued Alzheimer's disease; Bladder cancer; Gouty arthritis; Prostate cancer

Most Recent Events

  • 01 Feb 2017 Pfizer terminates a phase I trial in Uveitis (In adolescents, In adults, In the elderly) due to difficulty in recruitment in USA (NCT02131012)
  • 13 Nov 2016 Top-line efficacy data from the phase IV PRECISION trial in Rheumatic arthritis released by Pfizer
  • 15 Mar 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top